Ensign Peak Advisors Inc Trims Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Ensign Peak Advisors Inc decreased its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 25.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 267,949 shares of the company’s stock after selling 93,876 shares during the quarter. Ensign Peak Advisors Inc owned 0.31% of Syndax Pharmaceuticals worth $3,542,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Deutsche Bank AG grew its stake in shares of Syndax Pharmaceuticals by 35.7% during the 4th quarter. Deutsche Bank AG now owns 89,904 shares of the company’s stock worth $1,189,000 after purchasing an additional 23,634 shares during the period. DAFNA Capital Management LLC grew its stake in shares of Syndax Pharmaceuticals by 2.9% during the 4th quarter. DAFNA Capital Management LLC now owns 542,002 shares of the company’s stock worth $7,165,000 after purchasing an additional 15,300 shares during the period. Crestline Management LP grew its stake in shares of Syndax Pharmaceuticals by 66.4% during the 4th quarter. Crestline Management LP now owns 713,205 shares of the company’s stock worth $9,429,000 after purchasing an additional 284,667 shares during the period. Cubist Systematic Strategies LLC acquired a new stake in Syndax Pharmaceuticals in the 4th quarter valued at $4,734,000. Finally, Bayesian Capital Management LP acquired a new stake in Syndax Pharmaceuticals in the 4th quarter valued at $370,000.

Syndax Pharmaceuticals Stock Down 8.9%

Shares of SNDX opened at $9.28 on Thursday. Syndax Pharmaceuticals, Inc. has a 52-week low of $9.24 and a 52-week high of $25.07. The firm’s fifty day moving average is $12.33 and its two-hundred day moving average is $14.27. The stock has a market cap of $798.52 million, a PE ratio of -2.56 and a beta of 0.82.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its earnings results on Monday, May 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.04) by $0.06. The business had revenue of $20.04 million for the quarter, compared to analyst estimates of $15.88 million. During the same period last year, the firm earned ($0.85) EPS. The company’s revenue for the quarter was up 1900.0% compared to the same quarter last year. As a group, research analysts anticipate that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. JPMorgan Chase & Co. lifted their price target on shares of Syndax Pharmaceuticals from $39.00 to $41.00 and gave the company an “overweight” rating in a research note on Thursday, March 20th. Guggenheim reissued a “buy” rating and issued a $32.00 price target on shares of Syndax Pharmaceuticals in a research note on Tuesday, May 6th. Citigroup dropped their price target on shares of Syndax Pharmaceuticals from $45.00 to $42.00 and set a “buy” rating on the stock in a research note on Tuesday, March 4th. StockNews.com raised shares of Syndax Pharmaceuticals to a “sell” rating in a research note on Tuesday, May 6th. Finally, HC Wainwright reissued a “buy” rating and issued a $51.00 price target on shares of Syndax Pharmaceuticals in a research note on Tuesday, March 4th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $35.91.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).